Arcellx Inc
ACLX
Company Profile
Business description
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Contact
800 Bridge Parkway
Suite A
RedwoodCA94065
USAT: +1 240 327-0603
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
163
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
Guidance reaffirmed and UK implementation on track.
stocks
The sectors set to soar on government spending
Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks
Chart of the Week: How private companies are reshaping public markets
Our latest take from the US Manager Research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,121.90 | 13.60 | 0.15% |
| CAC 40 | 8,074.23 | 6.70 | 0.08% |
| DAX 40 | 24,049.74 | 100.63 | 0.42% |
| Dow JONES (US) | 47,311.00 | 225.76 | 0.48% |
| FTSE 100 | 9,777.08 | 62.12 | 0.64% |
| HKSE | 25,935.41 | 16.99 | -0.07% |
| NASDAQ | 23,499.80 | 151.16 | 0.65% |
| Nikkei 225 | 51,168.50 | 956.23 | 1.90% |
| NZX 50 Index | 13,632.65 | 11.67 | 0.09% |
| S&P 500 | 6,796.29 | 24.74 | 0.37% |
| S&P/ASX 200 | 8,852.50 | 15.70 | 0.18% |
| SSE Composite Index | 3,969.25 | 9.06 | 0.23% |